-
2
-
-
34247331726
-
Burden of symptomatic dengue infection in children at primary school in Thailand: a prospective study
-
Anderson K.B., Chunsuttiwat S., Nisalak A., Mammen M.P., Libraty D.H., Rothman A.L., et al. Burden of symptomatic dengue infection in children at primary school in Thailand: a prospective study. Lancet 2007, 369(April (9571)):1452-1459.
-
(2007)
Lancet
, vol.369
, Issue.APRIL 9571
, pp. 1452-1459
-
-
Anderson, K.B.1
Chunsuttiwat, S.2
Nisalak, A.3
Mammen, M.P.4
Libraty, D.H.5
Rothman, A.L.6
-
3
-
-
34247374654
-
The burden of dengue infection
-
PMID: 17467495
-
Halstead S.B., Suaya J.A., Shepard D.S. The burden of dengue infection. Lancet 2007, 369(April (9571)):1410-1411. PMID: 17467495. 10.1016/S0140-6736(07)60645-X.
-
(2007)
Lancet
, vol.369
, Issue.APRIL 9571
, pp. 1410-1411
-
-
Halstead, S.B.1
Suaya, J.A.2
Shepard, D.S.3
-
4
-
-
0002291194
-
The emergence of dengue/dengue hemorrhagic fever as a global public health problem
-
Elsevier, Paris, France, J.F. Saluzzo, B. Dodet (Eds.)
-
Gubler D.J. The emergence of dengue/dengue hemorrhagic fever as a global public health problem. Factors in the emergence of arbovirus diseases 1997, 83-92. Elsevier, Paris, France. J.F. Saluzzo, B. Dodet (Eds.).
-
(1997)
Factors in the emergence of arbovirus diseases
, pp. 83-92
-
-
Gubler, D.J.1
-
5
-
-
84876804736
-
The global distribution and burden of dengue
-
Bhatt S., Gething P.W., Brady O.J., Messina J.P., Farlow A.W., Moyes C.L., et al. The global distribution and burden of dengue. Nature 2013, 496(April (7446)):504-507. 10.1038/nature12060.
-
(2013)
Nature
, vol.496
, Issue.APRIL 7446
, pp. 504-507
-
-
Bhatt, S.1
Gething, P.W.2
Brady, O.J.3
Messina, J.P.4
Farlow, A.W.5
Moyes, C.L.6
-
6
-
-
84865988274
-
Refining the global spatial limits of dengue virus transmission by evidence-based consensus
-
Brady O.J., Gething P.W., Bhatt S., Messina J.P., Brownstein J.S., Hoen A.G., et al. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis 2012, 6(8):e1760. 10.1371/journal.pntd.0001760.
-
(2012)
PLoS Negl Trop Dis
, vol.6
, Issue.8
, pp. e1760
-
-
Brady, O.J.1
Gething, P.W.2
Bhatt, S.3
Messina, J.P.4
Brownstein, J.S.5
Hoen, A.G.6
-
7
-
-
0001422785
-
Flaviviruses
-
Lippincott Williams & Wilkins, D.M. Knipe, P.M. Howley (Eds.)
-
Burke D.S., Monath T.P. Flaviviruses. Fields virology 2001, 1043-1125. Lippincott Williams & Wilkins. D.M. Knipe, P.M. Howley (Eds.).
-
(2001)
Fields virology
, pp. 1043-1125
-
-
Burke, D.S.1
Monath, T.P.2
-
8
-
-
0036642434
-
Epidemiology of inapparent and symptomatic acute dengue virus infection: a prospective study of primary school children in Kamphaeng Phet, Thailand
-
Endy T.P., Chunsuttiwat S., Nisalak A., Libraty D.H., Green S., Rothman A.L., et al. Epidemiology of inapparent and symptomatic acute dengue virus infection: a prospective study of primary school children in Kamphaeng Phet, Thailand. Am J Epidemiol 2002, 156(July (1)):40-51. 10.1093/aje/kwf005.
-
(2002)
Am J Epidemiol
, vol.156
, Issue.JULY 1
, pp. 40-51
-
-
Endy, T.P.1
Chunsuttiwat, S.2
Nisalak, A.3
Libraty, D.H.4
Green, S.5
Rothman, A.L.6
-
9
-
-
79957782705
-
Dengue vaccines: progress and challenges
-
Coller B.A., Clements D.E. Dengue vaccines: progress and challenges. Curr Opin Immunol 2011, 23(June (3)):391-398. 10.1016/j.coi.2011.03.005.
-
(2011)
Curr Opin Immunol
, vol.23
, Issue.JUNE 3
, pp. 391-398
-
-
Coller, B.A.1
Clements, D.E.2
-
10
-
-
84883597357
-
Identifying protective dengue vaccines: guide to mastering an empirical process
-
Halstead S.B. Identifying protective dengue vaccines: guide to mastering an empirical process. Vaccine 2013, 31(September (41)):4501-4507. 10.1016/j.vaccine.2013.06.079.
-
(2013)
Vaccine
, vol.31
, pp. 4501-4507
-
-
Halstead, S.B.1
-
11
-
-
34250365710
-
Prospects for a dengue virus vaccine
-
Whitehead S.S., Blaney J.E., Durbin A.P., Murphy B.R. Prospects for a dengue virus vaccine. Nat Rev Microbiol 2007, 5(July (7)):518-528. 10.1038/nrmicro1690.
-
(2007)
Nat Rev Microbiol
, vol.5
, Issue.JULY 7
, pp. 518-528
-
-
Whitehead, S.S.1
Blaney, J.E.2
Durbin, A.P.3
Murphy, B.R.4
-
13
-
-
79959328055
-
Vaccines for the prevention of dengue: development update
-
Thomas S.J., Endy T.P. Vaccines for the prevention of dengue: development update. Hum Vaccines 2011, 7(6):674-684.
-
(2011)
Hum Vaccines
, vol.7
, Issue.6
, pp. 674-684
-
-
Thomas, S.J.1
Endy, T.P.2
-
14
-
-
80054989505
-
Next-generation dengue vaccines: novel strategies currently under development
-
Durbin A.P., Whitehead S.S. Next-generation dengue vaccines: novel strategies currently under development. Viruses 2011, 3(10):800-1814.
-
(2011)
Viruses
, vol.3
, Issue.10
, pp. 800-1814
-
-
Durbin, A.P.1
Whitehead, S.S.2
-
16
-
-
84920585186
-
Efficacy of a tetravalent dengue vaccine in children in Latin America
-
Villar L., Dayan G.H., Arredondo-García J.L., Rivera D.M., Cunha R., Deseda C., et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 2015, 372(January (2)):113-123. 10.1056/NEJMoa1411037.
-
(2015)
N Engl J Med
, vol.372
, Issue.JANUARY 2
, pp. 113-123
-
-
Villar, L.1
Dayan, G.H.2
Arredondo-García, J.L.3
Rivera, D.M.4
Cunha, R.5
Deseda, C.6
-
17
-
-
84908160975
-
Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial
-
Capeding M.R., Tran N.H., Hadinegoro S.R., Ismail H.I., Chotpitayasunondh T., Chua M.N., et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014, 384(October (9951)):1358-1365. 10.1016/S0140-6736(14)61060-6.
-
(2014)
Lancet
, vol.384
, Issue.OCTOBER 9951
, pp. 1358-1365
-
-
Capeding, M.R.1
Tran, N.H.2
Hadinegoro, S.R.3
Ismail, H.I.4
Chotpitayasunondh, T.5
Chua, M.N.6
-
18
-
-
84868211668
-
Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial
-
Sabchareon A., Wallace D., Sirivichayakul C., Limkittikul K., Chanthavanich P., Suvannadabba S., et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012, 380(November (9853)):1559-1567. 10.1016/S0140-6736(12)61428-7.
-
(2012)
Lancet
, vol.380
, Issue.NOVEMBER 9853
, pp. 1559-1567
-
-
Sabchareon, A.1
Wallace, D.2
Sirivichayakul, C.3
Limkittikul, K.4
Chanthavanich, P.5
Suvannadabba, S.6
-
19
-
-
84868215288
-
Dengue vaccine development: a 75% solution?
-
Halstead S.B. Dengue vaccine development: a 75% solution?. Lancet 2012, 380(November (9853)):1535-1536. 10.1016/S0140-6736(12)61510-4.
-
(2012)
Lancet
, vol.380
, Issue.NOVEMBER 9853
, pp. 1535-1536
-
-
Halstead, S.B.1
-
20
-
-
80052410152
-
The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease
-
Coller B.A., Clements D.E., Bett A.J., Sagar S.L., Ter Meulen J.H. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine 2011, 29(September (42)):7267-7275. 10.1016/j.vaccine.2011.07.021.
-
(2011)
Vaccine
, vol.29
, pp. 7267-7275
-
-
Coller, B.A.1
Clements, D.E.2
Bett, A.J.3
Sagar, S.L.4
Ter Meulen, J.H.5
-
21
-
-
77649270249
-
Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys
-
Clements D.E., Coller B.A., Lieberman M.M., Ogata S., Wang G., Harada K.E., et al. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 2010, 28(March (15)):2705-2715. 10.1016/j.vaccine.2010.01.022.
-
(2010)
Vaccine
, vol.28
, Issue.MARCH 15
, pp. 2705-2715
-
-
Clements, D.E.1
Coller, B.A.2
Lieberman, M.M.3
Ogata, S.4
Wang, G.5
Harada, K.E.6
-
22
-
-
0019979209
-
Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence
-
Henchal E.A., Gentry M.K., McCown J.M., Brandt W.E. Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. Am J Trop Med Hyg 1982, 31(July (4)):830-836.
-
(1982)
Am J Trop Med Hyg
, vol.31
, Issue.JULY 4
, pp. 830-836
-
-
Henchal, E.A.1
Gentry, M.K.2
McCown, J.M.3
Brandt, W.E.4
-
23
-
-
35348997373
-
ISCOMATRIX™ adjuvant for prophylactic and therapeutic vaccines
-
Drane D., Gittleson C., Boyle J., Maraskovsky E. ISCOMATRIX™ adjuvant for prophylactic and therapeutic vaccines. Exp Rev Vaccines 2007, 6:761-772.
-
(2007)
Exp Rev Vaccines
, vol.6
, pp. 761-772
-
-
Drane, D.1
Gittleson, C.2
Boyle, J.3
Maraskovsky, E.4
-
24
-
-
45749133490
-
Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses
-
Roehrig J.T., Hombach J., Barrett A.D. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol 2008, 21(June (2)):123-132. 10.1089/vim.2008.0007.
-
(2008)
Viral Immunol
, vol.21
, Issue.JUNE 2
, pp. 123-132
-
-
Roehrig, J.T.1
Hombach, J.2
Barrett, A.D.3
-
25
-
-
70749109995
-
Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy
-
Simmons M., Burgess T., Lynch J., Putnak R. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy. Virology 2010, 396(January (2)):280-288. 10.1016/j.virol.2009.10.023.
-
(2010)
Virology
, vol.396
, Issue.JANUARY 2
, pp. 280-288
-
-
Simmons, M.1
Burgess, T.2
Lynch, J.3
Putnak, R.4
-
26
-
-
22244477049
-
An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model
-
Robert Putnak J., Coller B.A., Voss G., Vaughn D.W., Clements D., Peters I., et al. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 2005, 23(August (35)):4442-4452.
-
(2005)
Vaccine
, vol.23
, Issue.AUGUST 35
, pp. 4442-4452
-
-
Robert Putnak, J.1
Coller, B.A.2
Voss, G.3
Vaughn, D.W.4
Clements, D.5
Peters, I.6
-
27
-
-
79960413988
-
ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells
-
Duewell P., Kisser U., Heckelsmiller K., Hoves S., Stoitzner P., Koernig S., et al. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells. J Immunol 2011, 187(July (1)):55-63. 10.4049/jimmunol.1004114.
-
(2011)
J Immunol
, vol.187
, Issue.JULY 1
, pp. 55-63
-
-
Duewell, P.1
Kisser, U.2
Heckelsmiller, K.3
Hoves, S.4
Stoitzner, P.5
Koernig, S.6
-
28
-
-
84862673527
-
ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases
-
Morelli A.B., Becher D., Koernig S., Silva A., Drane D., Maraskovsky E. ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases. J Med Microbiol 2012, 61(July (Pt 7)):935-943. 10.1099/jmm.0.040857-0.
-
(2012)
J Med Microbiol
, vol.61
, Issue.JULY Pt 7
, pp. 935-943
-
-
Morelli, A.B.1
Becher, D.2
Koernig, S.3
Silva, A.4
Drane, D.5
Maraskovsky, E.6
-
29
-
-
33748923173
-
Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques
-
Simmons M., Porter K.R., Hayes C.G., Vaughn D.W., Putnak R. Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques. J Virol 2006, 80(October (19)):9577-9585.
-
(2006)
J Virol
, vol.80
, Issue.OCTOBER 19
, pp. 9577-9585
-
-
Simmons, M.1
Porter, K.R.2
Hayes, C.G.3
Vaughn, D.W.4
Putnak, R.5
-
30
-
-
17444413399
-
Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys
-
Blaney J.E., Matro J.M., Murphy B.R., Whitehead S.S. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol 2005, 79(May (9)):5516-5528.
-
(2005)
J Virol
, vol.79
, Issue.MAY 9
, pp. 5516-5528
-
-
Blaney, J.E.1
Matro, J.M.2
Murphy, B.R.3
Whitehead, S.S.4
-
31
-
-
0034897886
-
Construction, safety and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine
-
Guirakhoo F., Arroyo J., Pugachev K.V., Miller C., Zhang Z.X., Weltzin R., et al. Construction, safety and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol 2001, 75(August (16)):7290-7304. 10.1123/JVI.75.16.7290-7304.2001.
-
(2001)
J Virol
, vol.75
, Issue.AUGUST 16
, pp. 7290-7304
-
-
Guirakhoo, F.1
Arroyo, J.2
Pugachev, K.V.3
Miller, C.4
Zhang, Z.X.5
Weltzin, R.6
-
32
-
-
45749111446
-
Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants
-
Eisenbarth S.C., Colegio O.R., O'Connor W., Sutterwala F.S., Flavell R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008, 453(June (7198)):1122-1126. 10.1038/nature06939.
-
(2008)
Nature
, vol.453
, Issue.JUNE 7198
, pp. 1122-1126
-
-
Eisenbarth, S.C.1
Colegio, O.R.2
O'Connor, W.3
Sutterwala, F.S.4
Flavell, R.A.5
-
33
-
-
84865353831
-
Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro
-
Ghimire T.R., Benson R.A., Garside P., Brewer J.M. Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro. Immunol Lett 2012, 147(September (1-2)):55-62. 10.1016/j.imlet.2012.06.002.
-
(2012)
Immunol Lett
, vol.147
, pp. 55-62
-
-
Ghimire, T.R.1
Benson, R.A.2
Garside, P.3
Brewer, J.M.4
-
34
-
-
4444260806
-
Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates
-
Guirakhoo F., Pugachev K., Zhang Z., Myers G., Levenbook I., Draper K., et al. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 2004, 78(May (9)):4761-4775.
-
(2004)
J Virol
, vol.78
, Issue.MAY 9
, pp. 4761-4775
-
-
Guirakhoo, F.1
Pugachev, K.2
Zhang, Z.3
Myers, G.4
Levenbook, I.5
Draper, K.6
-
35
-
-
0029811229
-
Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys
-
Putnak R., Barvir D.A., Burrous J.M., Dubois D.R., D'Andrea V.M., Hoke C.H., et al. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J Infect Dis 1996, 174(December (6)):1176-1184.
-
(1996)
J Infect Dis
, vol.174
, Issue.DECEMBER 6
, pp. 1176-1184
-
-
Putnak, R.1
Barvir, D.A.2
Burrous, J.M.3
Dubois, D.R.4
D'Andrea, V.M.5
Hoke, C.H.6
-
36
-
-
1642415963
-
Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand
-
Endy T.P., Nisalak A., Chunsuttitwat S., Vaughn D.W., Green S., Ennis F.A., et al. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis 2004, 189(March (6)):990-1000.
-
(2004)
J Infect Dis
, vol.189
, Issue.MARCH 6
, pp. 990-1000
-
-
Endy, T.P.1
Nisalak, A.2
Chunsuttitwat, S.3
Vaughn, D.W.4
Green, S.5
Ennis, F.A.6
-
37
-
-
84897932252
-
T-cell immunity to infection with dengue virus in humans
-
Weiskopf D., Sette A. T-cell immunity to infection with dengue virus in humans. Front Immunol 2014, March (5):93. 10.3389/fimmu.2014.00093.
-
(2014)
Front Immunol
, vol.March 5
, pp. 93
-
-
Weiskopf, D.1
Sette, A.2
-
38
-
-
79959328055
-
Vaccines for the prevention of dengue
-
Thomas S.J., Endy T.P. Vaccines for the prevention of dengue. Human Vaccines 2011, June (6):675-684.
-
(2011)
Human Vaccines
, vol.June 6
, pp. 675-684
-
-
Thomas, S.J.1
Endy, T.P.2
|